188813-08-3

Basic information

• Product Name: (3-bromo-5-iodophenyl)methanol
• Synonyms: (3-bromo-5-iodophenyl)methanol;3-Bromo-5-iodobenzyl alcohol
• CAS NO: 188813-08-3
• Molecular Formula: C₇H₆BrIO
• Molecular Weight: 312.93041
• Mol File: 188813-08-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (3-bromo-5-iodophenyl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (3-bromo-5-iodophenyl)methanol(188813-08-3)
• EPA Substance Registry System: (3-bromo-5-iodophenyl)methanol(188813-08-3)

Safety Data

• Hazardous Substances Data: 188813-08-3(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(3-bromo-5-iodophenyl)methanol is used as a building block in organic synthesis for the development of various pharmaceuticals and agrochemicals. Its unique structure allows for the creation of new compounds with potential applications in these fields.
Used in Chemical Research:
(3-bromo-5-iodophenyl)methanol is used as a reagent in chemical research for the synthesis of other organic compounds. Its versatility and unique properties make it a valuable tool in the development of new chemical reactions and processes.
Used in Drug Development:
(3-bromo-5-iodophenyl)methanol has potential applications in the development of new drugs and other bioactive molecules. Its unique structure and properties make it a promising candidate for the creation of novel therapeutic agents.
Used in Agrochemical Development:
(3-bromo-5-iodophenyl)methanol is also used in the development of new agrochemicals. Its unique structure and properties can contribute to the creation of innovative products for agricultural applications.

Upstream product

• 188815-32-9 3-bromo-5-iodo-benzoic acid 
• 188813-07-2 methyl 3-bromo-5-iodobenzoate 
• 7732-18-5 water 

Downstream Products

• 223463-19-2 1-Bromo-3-hexyloxymethyl-5-iodobenzene 
• 874331-77-8 1-bromo-3-iodo-5-(octyloxymethyl)benzene 
• 874331-78-9 1-bromo-3-[(trimethylsilyl)butadiynyl]-5-(octyloxymethyl)benzene 
• 874331-79-0 1-[(trimethylsilyl)butadiynyl]-3-(triisopropylsilyl)-5-(octyloxymethyl)benzene 
• 874331-86-9 1,4-bis[6-ethynyl-4-((octyloxy)methyl)phenyl-2-yl]buta-1,3-diyne 
• 874331-80-3 {3-[4-(3-bromo-5-octyloxymethyl-phenyl)-buta-1,3-diynyl]-5-octyloxymethyl-phenylethynyl}-triisopropyl-silane 
• 874331-82-5 {3-[4-(3-ethynyl-5-octyloxymethyl-phenyl)-buta-1,3-diynyl]-5-octyloxymethyl-phenylethynyl}-triisopropyl-silane 
• 874331-83-6 {3-[4-(3-bromoethynyl-5-octyloxymethyl-phenyl)-buta-1,3-diynyl]-5-octyloxymethyl-phenylethynyl}-triisopropyl-silane 
• 874331-81-4 C₅₀H₇₄O₂Si₂ 
• 874331-84-7 C₉₄H₁₃₀O₄Si₂ 
• 313691-56-4 2-(3-hexyloxymethyl-5-iodophenyl)-4,4,5,5-tetramethyl[1,3,2]dioxaborolane 
• 314250-11-8 1-hexyloxymethyl-3,5-diiodbenzene 
• 314250-10-7 1-hexyloxymethyl-3,5-bis(trimethylsilyl)benzene 
• 314250-12-9 2-bromo-5-[3-hexyloxymethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyridine 

Relevant articles and documents

Intrastrand foldamer crosslinking by reductive amination

A series of m-phenylene ethynylene (mPE) foldamers were crosslinked in their helical conformation using a reductive amination-based strategy. This was accomplished by placing aldehyde moieties in the backbone of the oligomer at specific residues, which al

NEW MACROCYCLIC LRRK2 KINASE INHIBITORS

Compounds of formula (I): wherein R, X1, X2, X3, Z1, Z2, Z3, A and Ra are as defined in the description. Medicaments.

Design and Optimization of 3′-(Imidazo[1,2- a]pyrazin-3-yl)-[1,1′-biphenyl]-3-carboxamides as Selective DDR1 Inhibitors

DDR1 is considered as a promising target for cancer therapy, and selective inhibitors against DDR1 over other kinases may be considered as promising therapeutic agents. Herein, we have identified a series of 3′-(imidazo[1,2-a]pyrazin-3-yl)-[1,1′-biphenyl]

NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME

Compound of formula (I): wherein A1, A2, Ra, Rb, Rc, Rd, R3, R4, X, Y and G are as defined in the description, and their use in the manufacture of medicaments.

Magnetic resonance imaging/fluorescence dual modality protocol using designed phosphonate ligands coupled to superparamagnetic iron oxide nanoparticles

A simple and versatile methodology to tailor the surface of superparamagnetic iron oxide nanoparticles (SPIONs), and render additional fluorescence capability to these contrast agents, is reported. The dual modality imaging protocol was developed by designing multi-functional scaffolds with a combination of orthogonal moieties for aqueous dispersion and stealth, to covalently link them to SPIONs, and carry out post-functionalization of nanoparticles. SPIONs stabilized with ligands incorporating surface-anchoring phosphonate groups, ethylene glycol backbone for aqueous dispersion, and free surface exposed OH moieties were coupled to near-infrared dye Cy5.5A. Our results demonstrate that design of multi-tasking ligands with desired combination and spatial distribution of functions provides an ideal platform to construct highly efficient dual imaging probes with balanced magnetic, optical and cell viability properties.

SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS

The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Designing miktoarm polymers using a combination of "click" reactions in sequence with ring-opening polymerization

The design and synthesis of a well-defined molecular building block with three orthogonal functionalities which facilitate the construction of ABC-type miktoarm star polymers via a combination of sequential CuI-catalyzed cycloaddition of an azi

3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS

The present invention relates to 3,4-substituted piperidinyl - based renin inhibitor compounds bearing at 4-position lsoqumolone and having the Formula (I) : The invention further relates to pharmaceutical compositions containing said compounds, as well a

3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS

The present invention relates to 3,4-substituted piperidinyl-based renin inhibitor compounds bearing at 4-position oxopyridine and having the formula (I). The invention further relates to pharmaceutical compositions containing said compounds, as well as their use in treating cardiovascular events and renal insufficiency.

META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS

The present invention relates to a class of compounds represented by the Formula Ior a pharmaceutically acceptable salt thereof, whereinA ispharmaceutical compositions thereof and methods of using such compounds and compositions as alphavbeta3 antagonists.